



# Circadian variations in cardiovascular disease

RICHARD CLINTON BECKER, MD AND JEANNE M. CORRAO, RN, MS

■ Circadian variations have been observed for a number of hemodynamic and cardiovascular events including heart rate, systemic blood pressure, coronary artery blood flow, ischemic cerebrovascular accidents, myocardial ischemia, myocardial infarction, and sudden cardiac death. In addition, circadian variations in platelet response to aggregating stimuli, plasma fibrinogen, coagulation factor concentration, and intrinsic fibrinolytic activity (as determined primarily by inhibitors of plasminogen activation) have been documented. Observed periodicities in thrombogenic capacity and cardiovascular events seem to correlate directly, suggesting a cause-effect relationship. Circadian variations in thrombotic tendency may influence the therapeutic response to anticoagulants and thrombolytic agents, particularly rt-PA. This area of cardiovascular disease is of profound clinical importance and warrants further investigation.

□ INDEX TERMS: CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; MYOCARDIAL INFARCTION □ CLEVELAND CLINIC JOURNAL OF MEDICINE 1989; 56:676-680

**T**HAT period of 24 hours, formed by the regular revolution of the earth, in which all its inhabitants partake, is particularly distinguished in the physical economy of man.... It is the unity of our natural economy.—C.W. Hufeland, *The art of prolonging life* [1797]<sup>1</sup>

Circadian variation (rhythm, periodicity) refers to a dynamic state in which biological systems change predictably and consistently over a 24-hour period, unique from fluctuations expected on the basis of temperature change and light-dark cycles. In humans, circadian variations have been identified for more than 100 psychologic and physiologic variables including adrenal, sympathetic/parasympathetic, hypothalamic, and pituitary activity. Therefore, all levels of metabolic function may be influenced.<sup>2</sup>

This review discusses circadian variations of cardiovascular disease, with particular emphasis on thrombus formation in the pathogenesis of myocardial infarction, daily fluctuations in thrombotic tendency, and its potential influence on treatment response.

## CIRCADIAN VARIATION IN HEMODYNAMIC AND CARDIOVASCULAR EVENTS

Circadian variations in hemodynamic parameters and cardiovascular events have been identified (*Table 1*). Daily fluctuations in heart rate, independent of physical activity, reflect similar variations in adrenal and sympathetic nervous system activity.<sup>3</sup> Neurohumoral activation is also the mechanism underlying changes in systemic blood pressure.<sup>4</sup> Continuous intraarterial monitoring has shown that systolic and diastolic blood pressures are lowest at 3 AM and highest at 10 AM.<sup>4</sup>

Thrombotic stroke is most frequently diagnosed in the late morning hours. Robertson et al<sup>5</sup> used the Stroke Data Bank, a multicenter trial initiated by the National Institute of Neurologic and Communicative Disorders and Stroke, to analyze the time of symptom onset for

From the Department of Cardiovascular Medicine, University of Massachusetts Medical Center, Worcester, MA. Submitted May 1988; accepted Jan 1989.

Address reprint requests to R.C.B., The Department of Cardiovascular Medicine, University of Massachusetts Medical Center, Worcester, MA 01605.

**TABLE 1**  
CIRCADIAN VARIATIONS IN CARDIOVASCULAR DISEASE

| Cardiac Event         | Time of peak level |
|-----------------------|--------------------|
| Heart rate            | 0900–1200          |
| Blood pressure        | 1000               |
| Stroke                | 0900–1200          |
| Arterial embolization | 0800–1600          |
| Myocardial blood flow | 1600               |
| Myocardial ischemia   | 0600–1200          |
| Myocardial infarction | 0600–1200          |
| Sudden cardiac death  | 0600–1200          |

1700 cases of confirmed stroke. The frequency was lowest in the early morning hours and highest between 9 AM and noon.<sup>5</sup> In-hospital progression of defined neurologic deficits also followed this pattern. Patients with mitral valve disease, particularly those with atrial fibrillation, are more likely to experience symptomatic arterial embolization between 8 AM and 4 PM than during other time intervals.<sup>6</sup>

The dynamic nature of intravascular blood flow has prompted investigators to search for a circadian variation in coronary blood flow. Indeed, coronary blood flow velocity, as determined with Doppler flow probes in dogs, is significantly lower between 8 and 9 AM than at other times of the day or night.<sup>7</sup> Such changes are independent of heart rate, blood pressure, left-ventricular end-diastolic pressure, peak dP/dt, end-diastolic regional myocardial dimension, and regional myocardial stroke work.<sup>7</sup> A circadian variation in vasomotor tone has also been identified in patients with coronary arterial spasm (Prinzmetal's angina),<sup>8</sup> which may involve periodicities in parasympathetic nervous system outflow.<sup>9–11</sup>

Patients with ischemic coronary heart disease frequently experience angina pectoris in the morning hours after awakening from sleep. Exercise-related ST segment depression, as observed during diagnostic exercise tolerance testing, occurs at lower heart rates in the morning compared with the afternoon.<sup>12</sup> Continuous ambulatory monitoring in patients with known coronary artery disease has allowed identification of a circadian variation in ischemic ST-segment events occurring between 6 AM and noon.<sup>13</sup> As with changes in myocardial blood flow, these events are independent of determinants of myocardial oxygen demand such as heart rate, blood pressure, and physical activity.

The observed circadian variations in myocardial blood flow, intravascular thrombotic events, and myocardial ischemia has prompted investigations of similar periodicities in myocardial infarction and sudden car-

diac death. Numerous epidemiologic studies performed in Europe,<sup>14,15</sup> Hungary,<sup>16</sup> Sweden,<sup>17</sup> Great Britain,<sup>18,19</sup> the Soviet Union,<sup>20</sup> and the United States<sup>21,22</sup> have documented a peak symptom onset for myocardial infarction between 6 AM and noon. An identical circadian variation has been identified in the frequency of sudden cardiac death, defined as death from cardiac disease occurring less than or equal to 1 hour after the onset of symptoms.<sup>23–26</sup>

#### THROMBOGENESIS AND CORONARY HEART DISEASE

The major pathophysiologic event underlying acute coronary syndromes, including myocardial infarction, is intracoronary thrombosis. Coronary angiography performed during the early stages of an evolving transmural infarction (less than 4 hours from symptom onset) reveals complete vessel occlusion in an overwhelming majority of cases.<sup>27</sup> Given this important fact, two questions must be addressed: "Are individuals with coronary heart disease predisposed to intracoronary thrombosis?" and if so, "Are there circadian variations in thrombotic tendency?"

Coronary atherosclerosis with resulting endothelial disruption, cross-sectional luminal narrowing, and alterations in laminar blood flow increases the likelihood of thrombus formation through a number of local mechanisms including enhanced platelet activation, decreased vascular PGI<sub>2</sub> synthesis/release, decreased endothelial-derived relaxing factor (EDRF) synthesis/release, and decreased plasminogen activator synthesis/release. In addition, patients with coronary heart disease, including those with chronic stable angina, accelerated angina, and/or nonfatal myocardial infarction, frequently exhibit systemic abnormalities in the hemostatic mechanism that predispose them to intracoronary thrombosis. A significant increase in serum fibrinogen and plasminogen activator inhibitor (PAI), coupled with a decrease in t-PA antigen and activity, may explain the enhanced capacity to form, and decreased capacity to lyse, blood clots in these patients.<sup>28–34</sup>

Daily variations in plasma fibrinogen, platelet aggregation, partial thromboplastin time (PTT), thrombin time (TT), and serum antithrombin III concentration have been observed in both patients with vascular disease and healthy controls. The tendency toward thrombus formation, as reflected by these parameters, is more pronounced in patients with vascular disease and, in fact, normal circadian variations may be attenuated.<sup>35</sup> In vitro platelet response to aggregating stimuli, such as adenosine diphosphate (ADP) and epinephrine, is ac-

**TABLE 2**  
TIME OF THROMBOLYTIC THERAPY AND RESPONSE RATES

| Time of Treatment | Patients |       | Lysis (+) |       | Lysis (-) |       | % Success |       | P Value* |
|-------------------|----------|-------|-----------|-------|-----------|-------|-----------|-------|----------|
|                   | SK       | rt-PA | SK        | rt-PA | SK        | rt-PA | SK        | rt-PA |          |
| 0000-0600         | 1        | 2     | 1         | 0     | 0         | 2     | 100       | 0     | ns       |
| 0600-1200         | 6        | 9     | 4         | 3     | 2         | 6     | 67        | 33    | ns       |
| 1200-1800         | 11       | 12    | 7         | 9     | 4         | 3     | 64        | 75    | ns       |
| 1800-2400         | 2        | 5     | 1         | 5     | 1         | 0     | 50        | 100   | ns       |
| Total             | 20       | 28    | 13        | 17    | 7         | 11    | 65        | 61    | ns       |
| 0000-1200         | 6        | 11    | 5         | 3     | 1         | 8     | 83        | 27    | ns       |
| 1200-2400         | 14       | 17    | 8         | 14    | 6         | 3     | 57        | 82    | ns       |

SK = streptokinase; rt-PA = recombinant tissue-type plasminogen activator; ns = not statistically significant.

\* = 2-sided (differences in lysis between SK and rt-PA for each time interval).

(Reprinted with permission<sup>60</sup>)**TABLE 3**  
COMPARISON OF RATES OF THROMBOLYSIS FOR rt-PA BETWEEN TREATMENT TIME INTERVALS

| Time      | % Lysis |    | Time      | % Lysis | P Value* |
|-----------|---------|----|-----------|---------|----------|
| 0000-0600 | 0       | vs | 0600-1200 | 33      | ns       |
| 0000-0600 | 0       | vs | 1200-1800 | 75      | ns       |
| 0000-0600 | 0       | vs | 1800-2400 | 100     | .0477†   |
| 0600-1200 | 33      | vs | 1200-1800 | 75      | ns       |
| 0600-1200 | 33      | vs | 1800-2400 | 100     | .0310†   |
| 1200-1800 | 75      | vs | 1800-2400 | 100     | ns       |
| 0000-1200 | 27      | vs | 1200-2400 | 82      | .0062†   |
| 0600-1800 | 57      | vs | 1800-0600 | 71      | ns       |

ns = not statistically significant.

\* = 2-sided.

† = statistically significant.

(Reprinted with permission<sup>60</sup>)

centuated during the morning hours, particularly after arising from sleep.<sup>36,37</sup> Similar variations in platelet receptor binding affinity (alpha<sub>2</sub>-adrenoreceptor) may explain this finding.<sup>38</sup>

Systemic fibrinolytic activity, as measured by fibrin plate analysis, undergoes daily fluctuations with lowest activity at 8 AM and highest between 5 and 8 PM.<sup>39,40</sup> Increased fibrinolytic activity following physical exercise is attenuated during the morning hours, most likely due to an increased serum PAI concentration during this period.<sup>40-43</sup>

Circadian variations in serum PAI concentration have been observed in patients with angiographically documented coronary heart disease, with peak levels occurring between 6 and 8 AM.<sup>44,45</sup> Patients with unstable angina pectoris have similar variations and, moreover, have been shown to have an elevated serum PAI concentration in samples taken immediately preceding evolution to acute myocardial infarction.<sup>45</sup> Fibrinolytic ac-

tivity commonly shows an inverse correlation with serum PAI concentration, reflecting its potentially critical role in overall hemostatic balance.<sup>46</sup>

#### TREATMENT: CIRCADIAN VARIATIONS AND RESPONSE TO THROMBOLYTIC AGENTS

As discussed, patients with coronary heart disease have a marked predisposition to intracoronary thrombosis. The daily fluctuation in serum coagulation factors, platelet aggregability, and fibrinolytic capacity may be the pathophysiologic substrate of observed thrombotic events. As therapeutic options for myocardial infarction evolve, circadian variations in thrombotic tendency and response to thrombolytic therapy must be explored.

In patients with venographically documented venous thrombosis, systemic anticoagulation with continuous intravenous heparin, as assessed by the PTT, TT, and factor Xa inhibition assay, follows a circadian variation

with maximum values at night and minimum values in the morning.<sup>47</sup> Since night and morning values may vary by as much as 50%, daily dose adjustments may prove to be warranted to avoid periods of excessive or inadequate systemic anticoagulation.<sup>47</sup>

The potential influence of serum PAI concentration on treatment response to thrombolytic agents, particularly recombinant tissue plasminogen activator (rt-PA), is receiving increased attention. Fibrin clots prepared from endogenous t-PA-rich plasma lyse spontaneously within a few hours, whereas clots prepared from t-PA-poor plasma do not undergo spontaneous lysis, nor do they lyse with the addition of exogenous t-PA.<sup>48,49</sup> This finding suggests that incorporation of endogenous t-PA into a clot as it forms is a prerequisite for subsequent lysis and that a reduced concentration of endogenous t-PA (or an elevated concentration of PAI) could impair the lytic response to exogenous rt-PA.

#### THROMBOLYTIC RESPONSE TO rt-PA IN ACUTE MYOCARDIAL INFARCTION

Under normal conditions, the overall effect of serum PAI concentration on thrombolytic response to rt-PA in acute myocardial infarction appears to be minimal, given the doses currently used in clinical practice and the serum t-PA antigen concentrations achieved.<sup>50</sup> However, a number of critical points must be considered: patients with coronary heart disease frequently have significantly elevated PAI activity<sup>30,32-34</sup>; latent PAI exists in plasma and may become activated following cell-surface binding<sup>51</sup>; the local concentration of PAI in the area of thrombotic occlusion may be markedly elevated as a result of endothelial, subendothelial, and platelet release.<sup>52-55</sup> Furthermore, patients receiving in-

travenous rt-PA as therapy for acute myocardial infarction have been shown to exhibit a marked decrease in serum t-PA activity, coupled with an increase in serum PAI activity, following completion of the rt-PA infusion.<sup>56,57</sup> Inefficient plasminogen activation, possibly the result of an elevated serum PAI concentration, may also explain the variability in fibrinolytic activity and clinical response in patients receiving intravenous rt-PA.<sup>58</sup> Furthermore, the ability to decrease serum PAI concentration pharmacologically and subsequently increase t-PA activity supports the potential modifying role of PAI in thrombolytic treatment response.<sup>59</sup>

Our interest in circadian variations in cardiovascular disease prompted an investigation to identify periodicities in thrombolytic response to either intravenous streptokinase or rt-PA. Forty-eight patients with angiographically documented subtotal or total coronary occlusion were randomly assigned to thrombolytic treatment during the early stages of acute myocardial infarction. Coronary artery reperfusion was assessed with serial coronary injections over a 90-minute period. In patients receiving streptokinase, coronary reperfusion was equally likely, regardless of the time of day when treatment was begun (Table 2). However, in patients treated with rt-PA between midnight and noon, reperfusion was four times less likely than in patients treated at other times of day (Table 3).<sup>60</sup>

While t-PA antigen, t-PA activity, and PAI concentration were not measured in this study, the recognized variations in fibrinolytic activity in patients with coronary heart disease during the morning hours suggests that our observation, at the very least, requires further investigation. If verified, its clinical implications would be significant.

#### REFERENCES

- Hufeland CW. Quoted by: Bunning E, ed. *The physiological clock. Circadian rhythms and biological chronometry*. London, English Universities Press, 1973.
- Suda M, Hayaishi O, Nakagawa H, eds. *Biological Rhythms and their Control Mechanism*. New York, Elsevier, 1979.
- Wertheimer L, Hassen AZ, Delman A. The 24 hour (circadian) rhythm of the cardiovascular system (abst). *Clin Research* 1972; 20:404.
- Millar-Craig MW, Bishop CN, Rafferty EB. Circadian variation of blood pressure. *Lancet* 1978; 1:795-797.
- Robertson T, Marler J, Muller J. Circadian variations in the frequency of onset of stroke (abst). *J Am Coll Cardiol* 1986; 7:40A.
- Dewar HA, Weightman D. A study of embolism in mitral valve disease and atrial fibrillation. *Br Heart J* 1983; 49:133-140.
- Fujita M, Franklin D. Diurnal changes in coronary blood flow in conscious dogs. *Circulation* 1987; 76:488-491.
- Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, Tanaka S. Circadian variation of exercise capacity in patients with Prinzmetal's variant angina: role of exercise-induced coronary arterial spasm. *Circulation* 1979; 59:938-948.
- Becker RC, Alpert JS. Nocturnal diaphoresis in Prinzmetal angina (letter). *Ann Int Med* 1987; 107:121.
- Becker RC, Giuliani M, Alpert JS. Nocturnal diaphoresis and coronary artery spasm: contribution of the parasympathetic nervous system. *Cleve Clin J Med* 1987; 54:515-518.
- Becker RC, Alpert JS. Variant angina pectoris: is the parasympathetic nervous system at fault (editorial)? *Chest* 1987; 92:963-965.
- Yasue H, Omote S, Takizawa A, et al. Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs. *Jpn Circ J* 1978; 42:1-10.
- Rocco MB, Barry J, Campbell S, Nabel EG, Rebecca ES, Selwyn AP. Circadian variation of transient myocardial ischemia (abst). *J Am Coll Cardiol* 1986; 7:191A.
- Willich SN, Linderer T, Wegscheider K, Schroder R. Increased risk of myocardial infarction in the morning (abst). *J Am Coll Cardiol* 1988; 11(Suppl A):28A.
- Myocardial Infarction Community Register: Results of a WHO international collaborative study coordinated by the Regional Office for

- Europe. [In] Public Health in Europe No. 5. Copenhagen, 1976 pp 1-232.
16. Gyasfas I, Csukas A, Hovath-Gaudi I. Analysis of the diurnal periodicity of acute MI attacks. *Sante Publique (Bucur)* 1976; 19:77-84.
17. Johansson BW. Myocardial infarction in Malmö 1960-1968. *Acta Med Scand* 1972; 191:505-515.
18. Pedoe HT, Clayton D, Morris JN, Brigden W, McDonald L. Coronary heart-attacks in East London. *Lancet* 1975; 2:833-838.
19. Thompson DR, Blandford RL, Sutton TW, Marchant PR. Time of onset of chest pain in acute myocardial infarction. *Int J Cardiol* 1985; 7:139-146.
20. Genelina IE, Borisova IY. Circadian rhythm of working capacity, sympathoadrenal activity, and myocardial infarction. *Human Physiol* 1983; 9:113-120.
21. Kaufman MW, Gottlieb G, Kahaner K, et al. Circadian rhythm and myocardial infarct: a preliminary study. *IRCS J Med Sci (Biochem)* 1981; 9:557.
22. Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. *N Engl J Med* 1985; 313:1315-1322.
23. Smolensky M, Halberg F, Sargent F. Chronobiology of life sequence. [In] Itolf S, Ogata K, Yashimura H, eds. *Advances in Climatic Physiology*. New York, Springer-Verlag, 1972, pp 281-318.
24. Mitler MM, Hajdukovic RM, Hahn PM, Kripke DE. Circadian rhythm of death time: causes of death versus recorded death time in New York City (abst). *Sleep Res* 1985; 14:306.
25. Otto W, Hempel WE, Wagner CU, Best A. Some periodical and aperiodical variations of mortality from myocardial infarction in the German Democratic Republic (abst). *Z Gesamte Inn Med* 1982; 37:756.
26. Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. *Circulation* 1987; 75:131-138.
27. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. *N Engl J Med* 1980; 303:897-902.
28. Chakrabarti R, Fearnley GR, Hocking ED, Delitheus A, Clarke GM. Fibrinolytic activity related to age in survivors of myocardial infarction. *Lancet* 1966; 1:573-574.
29. Chakrabarti R, Hocking ED. Fibrinolytic activity and coronary artery disease. *Lancet* 1968; 1:987-990.
30. Juhan-Vague I, Moerman B, DeCock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. *Thromb Res* 1984; 33:523-530.
31. Walker ID, Davidson JF, Hutton I, Lawrie TDV. Disordered fibrinolytic potential in coronary heart disease. *Thromb Res* 1977; 10:509-520.
32. Hamsten A, Wiman B, DeFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. *N Engl J Med* 1985; 313:1557-1563.
33. Francis RB Jr, Kawanishi D, Baruch T, Mahler P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. *Am Heart J* 1988; 115:776-780.
34. Leon MB, Glas-Greenwalt P, Pollack VE, Rosing DR, Epstein SE. Abnormal fibrinolytic activity in patients with CAD: improvement with long-term thrombolytic therapy with anecrod (abst). *J Am Coll Cardiol* 1985; 5:413.
35. Petralito A, Gibiino S, Maino MF, Mangiafico RA, Cuffari MG, Fiore CE. Daily modification of plasma fibrinogen, platelet aggregation, Howell's time, PTT, TT and antithrombin III in normal subjects and in patients with valvular disease. *Chronobiologica* 1982; 9:195-201.
36. Tofler GH, Czeisler CA, Rutherford J, Williams GH, Muller JE. Increased platelet aggregability after arising from sleep (abst). *J Am Coll Cardiol* 1986; 7:116A.
37. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. *N Engl J Med* 1987; 316:1514-1518.
38. Mehta JL, Lawson D, Mehta P, Lopez L. Circadian variation in platelet aggregation and alpha 2 adrenoceptor binding affinity (abst). *Circulation* 1987; 76(suppl IV):IV-364.
39. Fearnley GR, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm, with a simple method of measuring natural fibrinolysis. *Clin Sci* 1957; 16:645-650.
40. Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. Impairment of the diurnal fibrinolytic response in man: effects of aging, type IV hyperlipoproteinemia, and coronary artery disease. *Circulation Res* 1973; 32:752-758.
41. Cash JD. Effect of moderate exercise on the fibrinolytic system in normal men and women. *Br Med J* 1966; 2:502-506.
42. Cash JD, Allan AGE. The fibrinolytic response to moderate exercise and intravenous adrenaline in the same subjects. *Br J Haemat* 1967; 13:376-383.
43. Hafenberg J, Weber E, Spohr V, Morl H. Is the diurnal increase in fibrinolytic activity influenced by alpha-adrenergic or beta-adrenergic blockade? *Blut* 1980; 41:455-458.
44. Angleton P, Chandler WL, Schmer G. Diurnal variation in tissue plasminogen activator and its rapid inhibitor. *Circulation* 1987; 76(suppl IV):IV-339.
45. Huber K, Resch I, Rosc D, Glogar DH, Binder BR. Thrombotic complications in acute CAD can be correlated with elevated plasminogen activator inhibitor levels in plasma (abst). *Circulation* 1987; 76(suppl IV):IV-101.
46. Andreotti F, Khan MI, deBart A, et al. Circadian fluctuations in endothelium-derived fibrinolytic factors in relation to the time of onset of myocardial infarction and sudden cardiac death (abst). *J Am Coll Cardiol* 1988; 11(Suppl A):27A.
47. Decousus HA, Croze M, Levi FA, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. *Br Med J* 1985; 290:341-344.
48. Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficacy of activators added afterwards. *Thromb Res* 1984; 34:109-115.
49. Zamarron C, Lijnen HR, Collen D. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysis of clots in a plasma milieu in vitro. *Thromb Res* 1984; 35:335-345.
50. Bachman F, Kruithof EKO. Tissue plasminogen activator: chemical and physiologic aspects. *Sem Throm Hemostas* 1984; 10:6-17.
51. Lambers JWJ, Cammenga M, Konig B, Pannekoeck H, van Mourik JA. Activation of human endothelial cell type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. *Thromb Haemost* 1987; 58:8A.
52. Loskutoff DJ. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. *Sem Thromb Hem* 1988; 14:100-109.
53. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. *J Clin Invest* 1984; 74:1465-1472.
54. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor B: biological function and chemical structure. *Science* 1986; 233:532-534.
55. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. *Circulation* 1988; 77:670-677.
56. Lucore CL, Nadrowiak D, Sobel BE. Attenuation of t-PA activity by inhibitors in patients undergoing coronary thrombolysis (abst). *Circulation* 1987; 76(suppl IV):IV-306.
57. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. *Circulation* 1988; 77:660-669.
58. Barbash GI, Hod H, Rath S, et al. Intermittent, dose-related reocclusion during infusion of recombinant tissue plasminogen activator in myocardial infarction patients (abst). *Circulation* 1987; 76(suppl IV):IV-306.
59. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. *J Clin Invest* 1981; 68:1221-1228.
60. Becker RC, Corrao JM, Baker SP, Gore JM, Alpert JS. Circadian variation in thrombolytic response to recombinant tissue-type plasminogen activator in acute myocardial infarction. *J Appl Cardiol* 1988; 3:213-221.